As filed with the Securities and Exchange Commission on December 21, 2012

 

Registration No. 333-163443

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT No. 3 to

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

CHINA MEDICINE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada       51-0539830
(State or other jurisdiction
of incorporation or organization)
      (I.R.S. employer
identification No.)

 

Guangri Tower, Suite 702

No. 8 Siyou South 1st Street

Yuexiu District

Guangzhou, China 510600

(Address of principal executive offices) (zip code)

 

United Corporate Services, Inc.

202 South Minnesota Street

Carson City, Nevada 89703

(800) 899-8648

(Name and address of agent for service)

 

(800) 899-8648

(Telephone number, including area code, of agent for service)

 

Copy to:

Elizabeth Fei Chen, Esq.

Pryor Cashman LLP

7 Times Square

New York, NY 10036-6569

(212) 421-4100

 

Approximate date of commencement of proposed sale to the public: Not Applicable

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.     x

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

(Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company x

(Do not check if a smaller reporting company)

 

 
 

 

EXPLANATORY NOTE

 

This Post-Effective Amendment No. 3 to the Registration Statement on Form S-1, No. 333-163443, which was originally filed with the Securities and Exchange Commission (the “SEC”) on December 2, 2009 (the “Registration Statement”), of China Medicine Corporation (the “Company”), and was declared effective by the SEC on December 18, 2009, as amended by two Post-Effective Amendments to Form S-1, which were declared effective on January 19, 2010 and October 18, 2010, respectively, is being filed to terminate the effectiveness of the Registration Statement and remove from registration all securities previously registered under the Registration Statement which have been issued but not yet resold. The Registration Statement initially registered for resale a total of 3,169,212 shares of common stock, par value $.0001 per share (“Common Stock”), of the Company.

 

In the Company’s Current Report on Form 8-K, which was filed with the SEC on September 27, 2012, the Company announced its intention to deregister its Common Stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). On October 4, 2012, the Company filed a Form 15 to suspend its reporting obligations under Section 13 of the Exchange Act. The deregistration will become effective 90 days from the filing of the Form 15. In connection with such actions, the Company terminated the offering contemplated by the Registration Statement.

 

In accordance with an undertaking made by the Company in Part II of the Registration Statement to remove from registration, by means of a post-effective amendment, any securities which remain unsold at the termination of the offering, the company hereby amends the Registration Statement to remove from registration any and all shares of Common Stock registered under the Registration Statement which remain unsold.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has caused this Post-Effective Amendment No. 3 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Guangzhou in the People's Republic of China on this 21 st day of December, 2012.

 

      CHINA MEDICINE CORPORATION
         
      By: /s/ Senshan Yang
      Senshan Yang
      Chief Executive Officer
      (Principal Executive Officer)

 

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 3 to the Registration Statement was signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Senshan Yang   Chief Executive Officer   December 18, 2012
Senshan Yang   (Principal Executive Officer)    
         
/s/ Henry Ho      Chief Financial Officer     December 18, 2012
Henry Ho   (Principal Financial Officer)    
         
/s/ Rachel Gong   Director   December 18, 2012
Rachel Gong        
         
/s/ Ian Robinson   Director   December 18, 2012
Ian Robinson        
         
/s/ Ryan Shih      Director   December 17, 2012
Ryan Shih        

 

 

 

 

 

China Medicine (CE) (USOTC:CHME)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse China Medicine (CE)
China Medicine (CE) (USOTC:CHME)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse China Medicine (CE)